Arbutus Biopharma Corporation (ABUS)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ABUS Insider Trading Activity
ABUS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $284,292 | 5 | 100 |
Related Transactions
| MANCHESTER KEITH S | director | 0 | $0 | 1 | $32,637 | $-32,637 |
| Naftzger J. Christopher | General Counsel and CCO | 0 | $0 | 1 | $37,206 | $-37,206 |
| Sims Karen | Chief Medical Officer | 0 | $0 | 1 | $63,519 | $-63,519 |
| HASTINGS DAVID C | Chief Financial Officer | 0 | $0 | 1 | $72,827 | $-72,827 |
| McElhaugh Michael J. | Interim President & CEO | 0 | $0 | 1 | $78,103 | $-78,103 |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Activity of Arbutus Biopharma Corporation
Over the last 12 months, insiders at Arbutus Biopharma Corporation have bought $0 and sold $284,292 worth of Arbutus Biopharma Corporation stock.
On average, over the past 5 years, insiders at Arbutus Biopharma Corporation have bought $0 and sold $445,343 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $13,900 was made by HENRIQUES RICHARD C JR (director) on 2015‑08‑24.
List of Insider Buy and Sell Transactions, Arbutus Biopharma Corporation
| 2025-02-04 | Sale | McElhaugh Michael J. | Interim President & CEO | 23,790 0.0126% | $3.28 | $78,103 | -0.45% | |
| 2025-02-04 | Sale | HASTINGS DAVID C | Chief Financial Officer | 22,183 0.0117% | $3.28 | $72,827 | -0.45% | |
| 2025-02-04 | Sale | Sims Karen | Chief Medical Officer | 19,348 0.0102% | $3.28 | $63,519 | -0.45% | |
| 2025-02-04 | Sale | Naftzger J. Christopher | General Counsel and CCO | 11,333 0.006% | $3.28 | $37,206 | -0.45% | |
| 2024-08-14 | Sale | MANCHESTER KEITH S | director | 8,846 0.0048% | $3.69 | $32,637 | -4.89% | |
| 2024-02-02 | Sale | McElhaugh Michael J. | Interim President & CEO | 10,164 0.0057% | $2.31 | $23,504 | +40.76% | |
| 2024-02-02 | Sale | Sofia Michael J. | Chief Scientific Officer | 9,982 0.0056% | $2.31 | $23,083 | +40.76% | |
| 2024-02-02 | Sale | HASTINGS DAVID C | Chief Financial Officer | 9,593 0.0054% | $2.31 | $22,184 | +40.76% | |
| 2024-02-02 | Sale | Sims Karen | Chief Medical Officer | 4,358 0.0024% | $2.31 | $10,078 | +40.76% | |
| 2021-12-01 | Sale | Sofia Michael J. | Chief Scientific Officer | 200,000 0.218% | $5.09 | $1.02M | -44.14% | |
| 2021-02-09 | Sale | McElhaugh Michael J. | Chief Business Officer | 20,000 0.0239% | $5.00 | $100,000 | -25.28% | |
| 2020-12-14 | Sale | McElhaugh Michael J. | Chief Business Officer | 40,000 0.0439% | $5.00 | $200,032 | -29.51% | |
| 2020-07-23 | Sale | McElhaugh Michael J. | Chief Business Officer | 20,000 0.0203% | $5.01 | $100,200 | -46.45% | |
| 2018-08-13 | Sale | Sofia Michael J. | Chief Scientific Officer | 4,250 0.0076% | $9.51 | $40,436 | -60.00% | |
| 2018-07-11 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.017% | $10.00 | $100,000 | -61.98% | |
| 2018-07-09 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0183% | $8.91 | $89,060 | -53.41% | |
| 2018-07-06 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0166% | $8.45 | $84,500 | -55.27% | |
| 2018-07-05 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0167% | $8.40 | $84,000 | -54.73% | |
| 2018-07-03 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0174% | $8.00 | $80,000 | -50.24% | |
| 2017-10-03 | Sale | Sofia Michael J. | Chief Scientific Officer | 20,000 0.0392% | $8.00 | $160,000 | -21.85% |
Insider Historical Profitability
| McElhaugh Michael J. | Interim President & CEO | 1481003 0.7816% | $4.84M | 0 | 5 | |
| HASTINGS DAVID C | Chief Financial Officer | 159724 0.0843% | $522,297.48 | 0 | 2 | |
| Sims Karen | Chief Medical Officer | 106194 0.056% | $347,254.38 | 0 | 2 | |
| Naftzger J. Christopher | General Counsel and CCO | 86244 0.0455% | $282,017.88 | 0 | 1 | |
| MANCHESTER KEITH S | director | 46069 0.0243% | $150,645.63 | 0 | 1 | |
| Sofia Michael J. | Chief Scientific Officer | 1485121 0.7837% | $4.86M | 0 | 10 | |
| HENRIQUES RICHARD C JR | director | 1000 0.0005% | $3,270.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$678,065,999 | 37 | -13.32% | $630.85M | |
$94,912,877 | 34 | -7.15% | $613.49M | |
$16,271,606 | 27 | 24.11% | $537.23M | |
$149,456,352 | 27 | -8.77% | $703.25M | |
$6,280,187 | 19 | 6.80% | $532.42M | |
$22,007,592 | 17 | -0.43% | $631.46M | |
$124,557,176 | 16 | 29.13% | $571.94M | |
$109,488,423 | 15 | 56.69% | $700.29M | |
$4,210,269 | 14 | -15.87% | $633M | |
$133,809,976 | 13 | 31.29% | $552.93M | |
$9,976,473 | 12 | 29.52% | $783.34M | |
$1,229,070 | 10 | 23.53% | $516.91M | |
$11,541,901 | 10 | 8.07% | $576.59M | |
$135,543,039 | 9 | -5.28% | $582.74M | |
$1,580,951 | 9 | -14.18% | $527.78M | |
$20,499,451 | 9 | 71.54% | $752.55M | |
$91,721,700 | 9 | -13.73% | $634.67M | |
Arbutus Biopharma Corporation (ABUS) | $13,900 | 1 | -39.25% | $619.64M |
$504,640 | 1 | 16.84% | $754.07M |
ABUS Institutional Investors: Active Positions
| Increased Positions | 78 | +53.42% | 8M | +8.05% |
| Decreased Positions | 55 | -37.67% | 5M | -5.37% |
| New Positions | 22 | New | 2M | New |
| Sold Out Positions | 15 | Sold Out | 391,992 | Sold Out |
| Total Postitions | 169 | +15.75% | 104M | +2.68% |
ABUS Ownership Change vs Market
Institutional Investor Ownership
| Morgan Stanley | $74,085.00 | 11.95% | 22.59M | +878,467 | +4.05% | 2024-12-31 |
| Whitefort Capital Management, Lp | $43,433.00 | 7.01% | 13.24M | +373,949 | +2.91% | 2024-12-31 |
| Blackrock, Inc. | $42,435.00 | 6.85% | 12.94M | +718,695 | +5.88% | 2024-12-31 |
| Vanguard Group Inc | $29,457.00 | 4.75% | 8.98M | +62,282 | +0.7% | 2024-12-31 |
| Two Seas Capital Lp | $28,670.00 | 4.63% | 8.74M | +353,568 | +4.21% | 2024-12-31 |
| State Street Corp | $16,487.00 | 2.66% | 5.03M | +619,496 | +14.06% | 2024-12-31 |
| Geode Capital Management, Llc | $11,421.00 | 1.84% | 3.48M | +33,536 | +0.97% | 2024-12-31 |
| Blackbarn Capital Partners Lp | $7,681.00 | 1.24% | 2.34M | +270,971 | +13.09% | 2024-12-31 |
| Rubric Capital Management Lp | $5,514.00 | 0.89% | 1.68M | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $5,415.00 | 0.87% | 1.65M | -1M | -43.09% | 2024-12-31 |